beta pharmaceuticals|Oncology Research and Development : Cebu Beta Pharma | Our oncology pipeline includes non-small cell lung cancer drugs specifically targeting T790M NSCLC The jolly jerk is one of the most fascinating phenomena in the wide landscape of human behavior. This term, when used in a more informal context, perfectly describes someone whose mood swings from happy to angry with surprising ease.
beta pharmaceuticals,
Beta Pharma is dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology. Our products pipeline is diverse and undergoing rapid development.Beta Pharma, Inc. welcomes all guests to its website, www.betapharma.com. Beta Pharma’s website is designed to inform patients, health care professionals, caregivers, and others interested in oncology about our company and the treatments we provide.
Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology and virology. Our pipeline is diverse and undergoing rapid development.Oncology Research and Development Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology and virology. Our pipeline is diverse and undergoing rapid development.
beta pharmaceuticals Oncology Research and Development Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology and virology. Our pipeline is diverse and undergoing rapid development.Beta Pharma | Our oncology pipeline includes non-small cell lung cancer drugs specifically targeting T790M NSCLC
Beta Pharma, Inc. is an emerging specialty pharmaceutical company dedicated to the discovery, development, and commercialization of innovative late stage therapies targeting oncology.Beta Pharma looks to form pharmaceutical alliances and develop collaborations involving oncology therapeutics and technologies. Beta Pharma seeks diverse external partnering opportunities that will provide value to our patients and healthcare professionals within industry.Beta Chemicals evolved into Beta Pharma and in 1998 initiated its first drug discovery project. The first major breakthrough came in 2002 with the synthesis of a novel EGFR tyrosine kinase inhibitor, Icotinib.Beta Pharma | Our oncology pipeline includes drugs for breast cancer targeting metastatic breast cancer
Taking an innovative approach to drug development, Beta Pharma partnered with investors to pursue development of icotinib hydrochloride in China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior platinum-based chemotherapy regimen.
beta pharmaceuticals|Oncology Research and Development
PH0 · Privacy Policy
PH1 · Our Team
PH2 · Oncology Research and Development
PH3 · Oncology Pipeline – NSCLC Drugs
PH4 · News & Events
PH5 · Beta Pharma
PH6 · BPI